DoD Peer Reviewed Cancer, Clinical Trial Award

DoD Peer Reviewed Cancer, Clinical Trial Award is sponsored by Department of the Army -- USAMRAA. Supports rapid implementation of clinical trials with potential significant impact on cancer treatment or management within PRCRP topic areas.

A **. gov** website belongs to an official government organization in the United States.

* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.

gov Maintenance Calendar DOD Peer Reviewed Cancer, Clinical Trial Award Dept.

of the Army -- USAMRAA Document Type:Grants Notice Funding Opportunity Number:HT942525PRCRPCTA Funding Opportunity Title:DOD Peer Reviewed Cancer, Clinical Trial Award Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Science and Technology and other Research and Development Expected Number of Awards:8 Assistance Listings:12.

420 -- Military Medical Research and Development Cost Sharing or Matching Requirement:No Last Updated Date:Jun 06, 2025 Original Closing Date for Applications:Sep 25, 2025 Current Closing Date for Applications:Sep 25, 2025 Archive Date:Oct 25, 2025 Estimated Total Program Funding:$ 33,600,000 Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: ## Additional Information Agency Name:Dept.

of the Army -- USAMRAA Description:**Summary:**The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY25 PRCRP topic areas.

Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.

Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. **Distinctive Features:** • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III.

• If an Investigational New Drug Application (IND) or an Investigational Device Exemption (IDE) is required, the application must be submitted to the FDA prior to the FY25 PRCRP Clinical Trial Award application submission deadline (this includes clinical trials requesting exception from informed consent under Code of Federal Regulations, Title 21, Part 50. 24 (21 CFR 50. 24).

• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. **Funding Details:** (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs.

Link to Additional Information:[](https://grants. gov/search-results-detail/359096) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below.

This is being done to protect your privacy. Unsaved changes will be lost.